Commonwealth Bank of Australia lifted its holdings in shares of Eli Lilly and Co (NYSE:LLY) by 54.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 55,487 shares of the company’s stock after purchasing an additional 19,456 shares during the quarter. Commonwealth Bank of Australia’s holdings in Eli Lilly and were worth $4,741,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the company. MARSHALL WACE ASIA Ltd acquired a new position in Eli Lilly and in the 1st quarter valued at $4,840,000. Guardian Life Insurance Co. of America grew its stake in Eli Lilly and by 0.7% in the 1st quarter. Guardian Life Insurance Co. of America now owns 3,747 shares of the company’s stock valued at $315,000 after buying an additional 25 shares during the last quarter. Marshall Wace North America L.P. acquired a new position in Eli Lilly and in the 1st quarter valued at $4,840,000. Roosevelt Investment Group Inc. grew its stake in Eli Lilly and by 2.3% in the 1st quarter. Roosevelt Investment Group Inc. now owns 3,203 shares of the company’s stock valued at $269,000 after buying an additional 72 shares during the last quarter. Finally, Meiji Yasuda Asset Management Co Ltd. grew its stake in Eli Lilly and by 5.4% in the 1st quarter. Meiji Yasuda Asset Management Co Ltd. now owns 55,032 shares of the company’s stock valued at $4,629,000 after buying an additional 2,830 shares during the last quarter. Institutional investors own 76.30% of the company’s stock.

In related news, SVP Alfonso G. Zulueta sold 2,003 shares of Eli Lilly and stock in a transaction dated Friday, November 10th. The shares were sold at an average price of $83.67, for a total transaction of $167,591.01. Following the completion of the transaction, the senior vice president now directly owns 43,580 shares of the company’s stock, valued at approximately $3,646,338.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of Eli Lilly and stock in a transaction dated Wednesday, December 13th. The shares were sold at an average price of $88.20, for a total transaction of $17,640,000.00. Following the transaction, the insider now directly owns 123,084,104 shares of the company’s stock, valued at $10,856,017,972.80. The disclosure for this sale can be found here. Insiders have sold a total of 651,088 shares of company stock valued at $56,439,586 over the last ninety days. 0.20% of the stock is owned by insiders.

LLY has been the topic of a number of research analyst reports. Jefferies Group reiterated a “buy” rating and issued a $89.00 target price on shares of Eli Lilly and in a research note on Monday, September 11th. Piper Jaffray Companies reiterated a “buy” rating and issued a $103.00 target price on shares of Eli Lilly and in a research note on Thursday, August 31st. Goldman Sachs Group reiterated a “buy” rating and issued a $95.00 target price (up from $92.00) on shares of Eli Lilly and in a research note on Thursday, October 5th. Cowen reiterated a “buy” rating and issued a $95.00 target price on shares of Eli Lilly and in a research note on Wednesday, October 4th. Finally, Zacks Investment Research upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $95.00 target price on the stock in a research note on Thursday, October 26th. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have issued a buy rating to the company. Eli Lilly and currently has a consensus rating of “Hold” and a consensus target price of $90.25.

Eli Lilly and Co (NYSE:LLY) opened at $85.14 on Thursday. The company has a market cap of $93,670.16, a PE ratio of 40.35, a PEG ratio of 1.76 and a beta of 0.35. Eli Lilly and Co has a 1-year low of $72.97 and a 1-year high of $89.09. The company has a current ratio of 1.38, a quick ratio of 1.03 and a debt-to-equity ratio of 0.66.

Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 EPS for the quarter, topping analysts’ consensus estimates of $1.03 by $0.02. The company had revenue of $5.66 billion during the quarter, compared to the consensus estimate of $5.52 billion. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The firm’s revenue for the quarter was up 9.0% compared to the same quarter last year. During the same period last year, the firm earned $0.88 EPS. research analysts anticipate that Eli Lilly and Co will post 4.22 earnings per share for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 9th. Stockholders of record on Thursday, February 15th will be issued a dividend of $0.5625 per share. This represents a $2.25 dividend on an annualized basis and a dividend yield of 2.64%. This is an increase from Eli Lilly and’s previous quarterly dividend of $0.52. The ex-dividend date of this dividend is Wednesday, February 14th. Eli Lilly and’s dividend payout ratio (DPR) is presently 98.58%.

TRADEMARK VIOLATION WARNING: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://theolympiareport.com/2017/12/28/commonwealth-bank-of-australia-has-4-74-million-stake-in-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.